Despite their relative infrequency (which is often used as an excuse for poor treatment), soft-tissue sarcomas have been the focus of considerable interest and advances in recent years, mainly because of molecular genetic developments as well as evolution in their histological classification. In parallel, however, there remains no clear consensus regarding either the ideal biopsy technique (in this era of increasing outpatient management) or the best means of prognostication (particularly by histological grading). This review aims to discuss some of these recent developments and co-existent controversies. Aside from the understandable pursuit of modern biotechnological innovations, it seems that the most important goal remains the need to achieve more consistent primary surgical management of these tumours, preferably in specialist centres.